A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.

Autor:	Diaz-Pollan B; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP.; CIBERINFEC (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas), Instituto de Salud Carlos III, Madrid, ESP., Carrasco Molina S; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., Marcelo C; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., de Gea Grela A; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., Martínez-Martín P; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., Jiménez-González M; Clinical Trials Unit (UCICEC), Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., Moreno Ramos F; Pharmacy Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP., Mora-Rillo M; Internal Medicine Department, Infectious Diseases Unit, Hospital La Paz Institute for Health Research (IdiPAZ) Hospital Universitario La Paz, Madrid, ESP.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Nov 13; Vol. 15 (11), pp. e48735. Date of Electronic Publication: 2023 Nov 13 (Print Publication: 2023).
DOI:	10.7759/cureus.48735
Abstrakt:	Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recurrence and mortality in patients with CDI treated with either fidaxomicin or vancomycin. Methods A retrospective case-control study was conducted on patients with CDI treated with either fidaxomicin or vancomycin at a hospital from January 2019 to March 2022. Results We assessed 140 patients with CDI episodes, 70 patients treated with fidaxomicin and 70 with vancomycin. Seventy (50%) were male. Median age was 70 years old (IQR: 56-81). Fidaxomicin group had more recurrent CDI episodes within six months (59% vs 11%, p ≤ 0.001), more severity (43% vs 16%, p ≤ 0.001) and less treatment response (84% vs 100%, p ≤ 0.002) compared with vancomycin group. Recurrence and mortality rates in the follow-up period did not differ in both groups. Conclusions Our study found fidaxomicin treatment had worse outcomes due to restricted usage, potentially impacting its effectiveness in CDI. This finding is especially significant for patients with severe or recurrent CDI, as prescribing of the drug was limited until May 2022 in Spain with the lifting of this restriction, further research is necessary to better understand the potential benefits of fidaxomicin in treating CDI. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Diaz-Pollan et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu